• Home
  • Medinfo
  • Restarting Subcutaneous MabThera after Treatment Interruption

Restarting Subcutaneous MabThera after Treatment Interruption

This letter responds to your request for information on MabThera SC® (rituximab and hyaluronidase human) and restarting MabThera subcutaneous administration after a treatment interruption.

Download article Download

Last updated August 10, 2023

Mabthera SC treatment interruptions allowed in Roche pivotal trials

Roche has no recommendations on when to restart MabThera SC after a treatment interruption. We cannot provide therapeutic recommendations for individual patients.

However, treatment interruptions were allowed in pivotal studies to allow patients to recover from hematological toxicities, infections, or other clinical conditions that precluded treatment according to institutional practice.


Table 1 provides a summary of the pivotal trial study designs.

Indication of Study name ,Study design, Study objective Subcutaneous administration schedule, Duration in which delay was allowed & Maximum delay between 2 MabThera doses for 1L PL , 1L CLL and 1L DLBCL
Abbreviations: CHOP=chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone; CLL=chronic lymphocytic leukemia; CR=complete response; CRu=unconfirmed complete response; CVP=chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate, and prednisone; DLBCL=diffuse large b-cell lymphoma; FC=chemo regimen consisting of fludarabine and cyclophosphamide; FL=follicular lymphoma; IV=intravenous; N/A=not available; ORR=objective response rate (CR,CRu, & PR); PR=Partial Response; PK=Pharmacokinetics, SC=subcutaneous; 1L=1st line/previously untreated

Safety considerations for restarting MabThera SC

Clinicians should consider individual patient factors such as previous IRRs or ARRs, tumor burden and peripheral B-cell counts when deciding how to restart Mabthera SC after a dose interruption.

Previous infusion-related reactions (IRRs) and administration-related reactions (ARRs)

Patients are at the highest risk of experiencing an IRR from MabThera IV at Cycle 1. Patients with a high tumor burden may be at higher risk of developing severe IRRs.[6]

Restarting MabThera treatment with an IV-first dose after an extended delay or interruption of MabThera SC may help to manage ARRs because of the ability to control slowing or stopping the IV infusion.[6]

The rate of IRRs after varying intervals of treatment interruptions were not evaluated in pivotal studies.[6]


    1. Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 2017;4:e272-e282. https://www.ncbi.nlm.nih.gov/pubmed/28476440
      1. Roche Internal Clinical Study Report. (Accessed on 29 Jun 2023).
        1. Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016;3:e128-38. https://www.ncbi.nlm.nih.gov/pubmed/26947201
          1. Roche Internal Clinical Study Report. (Accessed on 26 Jun 2023).
            1. Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica 2017;102:1913-1922. https://www.ncbi.nlm.nih.gov/pubmed/28935843
              1. Roche Internal Regulatory Document. (Accessed on 26 Jun 2023).

                Welcome to Medically

                The Roche Science Hub

                This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                Not a healthcare professional? Browse:

                This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                You are Leaving Medically

                By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.